Close Menu

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Boston Medical Center are collaborating on a multi-year research study on biomarkers that indicate sensitivity and resistance to standard-of-care checkpoint inhibitors.

The goal of the study is to identify prognostic and predictive immuno-oncology biomarkers across different cancers. The researchers will explore not only tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.